Introduction
Insulin-like growth factor II mRNA-binding protein 3 (IMP3 or IGF2BP3) is a member of the RNA-binding protein family, which plays an important role in RNA trafficking and stabilization, cell growth, and cell migration during the early stages of embryogenesis.
1 IMP3 was proposed to control the translation or turnover of various candidate target genes, including IGF2, CD44, HMGA2, and MMP9. [2] [3] [4] [5] This oncofetal protein has been reported to promote tumor cell survival, proliferation, chemoresistance, and tumor cell invasiveness in vitro. In recent years, accumulating studies have shown that IMP3 is specifically expressed in malignant tumors and acts as an important cancer-specific gene involved in many aggressive and advanced cancers. the absence of association between IMP3 expression and cancer prognosis. 14, 15 Some investigators have also replayed completely opposite results in ovarian cancer. For instance, Kobel et al 16 proposed that IMP3 expression is a marker of unfavorable prognosis, whereas Noske et al 17 asserted that IMP3 expression is associated with improved survival. Hence, the prognostic role of IMP3 expression in solid tumors remains unclear and controversial.
Therefore, we conducted a systematic review of published studies, with a standard meta-analysis combining available evidence, to evaluate the prognostic value of IMP3 expression in solid tumors.
Materials and methods
This meta-analysis was conducted according to the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 18 (Table S1 ). Because the data included in this study were retrieved from published articles, ethical approval from ethics committees was not needed.
literature search
A comprehensive literature search was performed in PubMed, Embase, Web of Science, and Cochrane Library to identify studies evaluating IMP3 expression and clinical prognosis in solid tumors up to April 2016. The search strategy included the following terms through MeSH headings, keywords, and text words: "IMP3" or "Insulin-like growth factor 2 mRNA binding protein 3" or "IGF2BP3" combined with "cancer" or "carcinoma" or "neoplasm". The references cited in the identified articles were also screened for possible inclusions. The database search and preliminary evaluation of identified studies were performed independently by two investigators (LC and YX) . No language limitation existed in the process.
study selection
The inclusion criteria for selecting articles in our analysis are listed as follows: 1) studies that reported IMP3 expression in cancer tissues, 2) studies analyzing the relationship between IMP3 expression level and clinical cancer outcomes, 3) studies that directly reported survival outcomes with hazard ratio (HR) and corresponding 95% confidence interval (CI) or studies that provided sufficient data for estimating HR and 95% CI by using the methods described by Tierney et al, 19 and 4) studies with a median follow-up of at least 6 months. Studies were excluded if they were 1) case reports, letters, conference abstracts, or reviews, 2) non-human research, 3) investigations on the diagnostic role, but not the prognostic role, of IMP3, and 4) studies with insufficient data for calculating the HR and 95% CI. If duplicate publications by the same authors were retrieved, we included only the most informative and recent study. Two independent reviewers (LC and YX) evaluated the full articles for study eligibility, and any disagreement was resolved by consensus.
Data extraction and quality assessment
Two authors (LC and YX) independently extracted data from each eligible study by using predefined item forms. The following information, if available, was recorded: first author's name, year of publication, study country or region, type of cancer, cancer stage, number of patients, detected method, cutoff definition, percentage of high IMP3 expression, follow-up period, and survival outcomes with their HRs and corresponding 95% CIs. If univariate and multivariate analyses were reported to obtain the HRs, the results of multivariate analysis were preferentially selected. If HRs and 95% CIs were not provided directly, we attempted to estimate these points with Kaplan-Meier curve or other required data in the original study by using Tierney et al's methods. 19 Study quality was scored by two investigators (LC and YX) using the Newcastle-Ottawa Scale, which involves three main categories: selection, comparability, and outcome ascertainment. We defined studies with scores no less than 6 as qualified to be included in the meta-analysis. Discrepancies between investigators were resolved through discussion.
statistical analysis
Pooled HRs and corresponding 95% CIs were calculated to evaluate the prognostic role of high IMP3 expression in the clinical outcomes of solid tumors. An observed HR greater than 1 implied a worse prognosis in patients with high IMP3 expression, and an HR less than 1 indicated a better prognosis. Statistical heterogeneity of combined HR was assessed using Cochrane Q-test and Higgins I 2 metrics. I
2
.50% was considered a measure of obvious heterogeneity. 20 If no evident heterogeneity existed, the fixed-effect model (Mantel-Haenszel method) was used to pool the results. 21 Otherwise, the randomeffect model (DerSimonian and Laird method) was selected. 22 The potential sources for heterogeneity, if significant, were further explored using a predefined subgroup analysis and meta-regression analysis (based on cancer type, ethnicity, case number, cutoff, cancer stage, HR obtained method, and analysis method). To assess the stability of the pooled results, sensitivity analysis was performed by sequential omission of each single study. Publication bias was also estimated by OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
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Prognostic value of high iMP3 expression in solid tumors visually assessing the asymmetry of the funnel plot and then quantitatively evaluated by Begg's and Egger's tests. 23, 24 All the abovementioned analyses were performed using STATA version 12.0 (Stata Corporation, College Station, TX, USA). All statistical tests were two sided, and statistical significance was defined as a P-value less than 0.05.
Results
search results and study characteristics
The flowchart of the literature search is shown in Figure 1 . A total of 420 potentially relevant studies were retrieved from the initial literature search in the aforementioned electronic databases. A total of 144 duplicated records were excluded by a literature manager software. After carefully screening titles and abstracts of the remaining 120 records, 46 studies were excluded and 74 studies were selected for full-text assessment. Given the inclusion and exclusion criteria, 21 studies that belonged to duplicate publication or failed to offer sufficient prognostic information were excluded. Finally, 53 studies satisfied our eligibility criteria and were included in this meta-analysis. 67 and cervical cancer. 13 A total of 25 studies involved Caucasians and 28 involved Asians. The survival outcomes in these studies, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS), were investigated in 40, 10, 8, 7, 4 , and 5 studies, respectively. HRs were reported directly in most of these studies (43/53) and were estimated indirectly in the 10 other studies. Multivariate Cox Figure 2 ). The effect of IMP3 expression on OS was further analyzed by tumor types, and the results are presented in Figure 3A . stage is a potential significant contributor to heterogeneity (P=0.017), unlike other factors (P.0.05).
To assess the credibility of the pooled outcomes, we performed a sensitivity analysis through the sequential omission of individual studies. The results were not obviously influenced by any single study ( Figure 3C ). The publication bias of all included studies was evaluated using a vertical funnel plot, Begg's, and Egger's tests. However, the funnel plot in Figure 3B appears asymmetrical, and the Begg's (P=0.015) and Egger's tests (P=0.002) revealed existing evidence of publication bias, which may be attributed to only seven studies that reported negative results among all the enrolled studies.
association of iMP3 with css, DFs, rFs, PFs, and MFs
Ten studies that involved a total of 2,877 patients provided sufficient data for CSS analysis. No heterogeneity was observed among these studies (I 2 =31.3%, P=0.158). Thus, a fixed model was applied to pool the results. The combined 
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Prognostic value of high iMP3 expression in solid tumors Figure 3 Subgroup analysis of OS stratified by tumor types, funnel plot of OS for publication bias, and sensitive analysis of OS. Notes: (A) High IMP3 expression was significantly associated with poor OS in RCC, lung cancer, oral cancer, urothelial carcinoma, HCC, colorectal cancer, pancreatic cancer, gastric cancer, and icc but not in ovarian cancer. (B) The funnel plot for Os was asymmetric, which indicated the probability of publication bias. (C) sensitivity analysis by sequential omission of individual studies did not alter the significance, which confirmed the credibility of outcomes. Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; ICC, intrahepatic cholangiocarcinoma; In, natural logarithm; IMP3, insulin-like growth factor ii mrna-binding protein 3; Os, overall survival; rcc, renal cell carcinoma; se, standard error. Figure 5A ). For PFS, four studies with 457 patients were included in the analysis. A forest plot of study-specific HRs for PFS is presented in Figure 5B . The combined results indicated that high IMP3 expression was significantly associated with worse PFS in solid tumors (HR =2.18, 95% CI: 1.11-4.29, P=0.023). In addition, five studies, including 1,613 patients, focused on the influence of IMP3 on solid tumor metastasis. Meta-analysis of these studies suggested that IMP3 expression was also associated with poor MFS (HR =4.91, 95% CI: 2.05-11.73, P,0.001, Figure 5C ).
Discussion
Over the past decades, increasing correlative studies describe the elevated IMP3 expression in human cancers, and various functional in vitro or in vivo studies provide strong evidence indicating that this oncofetal protein serves an essential role in modulating tumor cell fate. 6 As a molecular biomarker, IMP3 has attracted extensive attention and can be used to distinguish different prognoses, improve prediction accuracy, and better guide clinical decisions in different tumor types. 7 Nevertheless, the relationship between IMP3 expression and oncological outcome remains controversial and requires a consensus. Consequently, we attempted to perform a systematic review of published relevant studies and conduct a meta-analysis to clarify the prognostic value of IMP3 expression in patients with solid tumors.
In the present research, given the inclusion criteria, 53 studies involving 8,937 patients were eligible, and the HRs of cumulative survival rates were summarized quantitatively by standard meta-analysis techniques. Our results suggested that high IMP3 expression was associated with worse OS of the solid tumors. in RCC, lung cancer, oral cancer, urothelial carcinoma, HCC, colorectal cancer, pancreatic cancer, gastric cancer, and ICC. Besides OS, we also investigated other frequently used survival outcomes, including CSS, DFS, RFS, PFS, and MFS. Similar influences were found for high IMP3 expression regarding the abovementioned end points, which provide a relatively comprehensive assessment of the value of IMP3 acting as a prognostic biomarker in solid tumors.
Accumulated literature suggests that IMP3 contributes to various aspects of cancer by promoting target genes expression by either preventing mRNA decay or stimulating mRNA translation. IMP3 knockdown in vitro can significantly inhibit the translation of IGF2 mRNA resulting in the marked inhibition of cell proliferation.
2 By using solid cancer transcriptome data, IMP3 was also found to be correlated with HMGA2 mRNA expression in a dose-dependent manner. Additional assay for elucidating the mechanism indicated that IMP3 may function as a cytoplasmic safe house and prevents miRNA-directed mRNA decay of HMGA2 during tumor progression. 4 Another recent study identified IMP3 as capable of directly binding the mRNAs of cyclins D1, D3, and G1 in vivo and in vitro. The study also found that IMP3 can regulate the expression of these cyclins depending on their protein partner HNRNPM in six human cancer cell lines of different origins. 68 In addition, IMP3 promotes tumor cell invasion and migration by targeting the epithelial-mesenchymal submit your manuscript | www.dovepress.com
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chen et al transition-associated molecular makers, including E-cadherin, Slug, and vimentin. 69 Overall, IMP3 plays an essential and multifaceted role in human cancers. Hence, targeting IMP3 may serve as a potential strategy for anticancer therapy.
To our knowledge, our study is the first meta-analysis that comprehensively evaluated the association between IMP3 expression and prognosis in patients with solid tumors. However, several limitations of our study must 
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Prognostic value of high iMP3 expression in solid tumors be acknowledged. First, we only extracted summarized population-level data rather than individual subject data from published literature. Second, different cutoff values and definitions of high IMP3 expression were used in these included studies. Third, a marked study heterogeneity existed in some analyses. The subgroup analyses and meta-regression revealed that cancer stage might be a significant contributor to heterogeneity. Moreover, several potential factors such as cancer type, cutoff value, baseline characteristics (sample size, sex, age, and pathological subtype), and duration of follow-up may partially contribute to the heterogeneity. Among the enrolled studies, 10 works did not directly report the HRs. The calculated HRs, which were estimated using the methods of Tierney et al, might not be as dependable as those retrieved directly from the reported results. As such, the HRs inevitably introduced some statistical errors and may have influenced the pooled analysis. Furthermore, some studies only provided univariate analysis results, which may have introduced a bias toward overestimation of the prognostic value compared with multivariate analysis. The funnel plot and Egger's test suggested the probability of publication bias because of fewer studies reporting negative results. However, the greater difficulty in publishing studies with insignificant results than those with significant results may be unavoidable. Finally, despite the well-recognized advantages of systematic review and meta-analysis, the results were based on the quality of the included studies. Thus, further high-quality studies with larger samples and a unified detection method are entailed to achieve a consensus on this matter.
Conclusion
The current evidence suggests that high IMP3 expression in tumor tissues is associated with adverse survival in various cancers. Hence, IMP3 might be a potential and promising biomarker that can be used to improve prognosis stratification and guide decision making in the treatment of solid tumors. Further well-designed studies are needed to confirm our findings and obtain more precise evaluations of the prognostic value of IMP3 in cancers. 4 study selection 9 state the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
5
Data collection process 10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.
5,6
risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; (b) effect estimates and confidence intervals, ideally with a forest plot.
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